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ABSTRACT 
Nigeria remains one of the major reservoirs for wild poliovirus transmission despite the reported success in National 
Immunization Days and acute flaccid paralysis surveillance. Two hundred children aged ≤ 10 years, were enrolled 
following parental consent from hard-to-reach riverine areas of Delta state of Nigeria to assess the level of protective 
immunity to poliovirus. Neutralizing antibodies to the three poliovirus serotypes in the serum samples of the children 
were determined by the beta method of neutralization.  
Eight (4%) of the children had no detectable antibody, 178 (89%), 180 (90%) and 181 (90.5%) were positive for antibodies to 
poliovirus types 1, 2 and 3, respectively. Overall, 162 (81%) of the children had antibodies to the three poliovirus serotypes 
at a titre of at least 1:8. The study shows the need for proper monitoring of vaccination coverage in such hard-to-reach 
riverine areas to achieve the objective of the global eradication of poliovirus. 
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INTRODUCTION 
In May 1988, the World Health Assembly (WHA) 
resolved to eradicate Poliomyelitis globally by the 
year 2000 (1).  The global eradication of polio 
involves both halting the incidence of the disease 
and the worldwide eradication of the virus. In the 
African Region (AFRO) of the World Health 
Organization (WHO), eradication strategies were 
accelerated following supporting resolutions by 
WHO’s Regional Committee for Africa in 1995 and 
the Organization for African Unity in 1996. 
Remarkable progress has been made since the 
initiative began in 1988 (2). 
 
However, there have been reports of less-than-
optimal responses to trivalent OPV in developing 
countries. Patriarca et al. (3) reviewed data that 
accumulated in developing countries over 25 years 
and found 32 studies from 15 developing countries 
on the response of children to three doses of 
trivalent Sabin-derived OPV. After three doses of 
trivalent OPV, there was wide variation in the 
proportion of children seroconverting with rates of 
73% for type 1, 90% for type 2, and 70% for type 3. 
Also, a large-scale randomized trial in Brazil and 
the Gambia has confirmed these findings. Even 
after eight OPV doses delivered during mass 
campaigns, gaps in immunity as defined by serum 
antibody levels, persist in some countries, 
especially for type 3 (4). 
 
Although there has been improvement in the 
quality of surveillance for acute flaccid paralysis 
(AFP) and synchronized house-to-house NIDs 
conducted since late 2000 in Nigeria, the country 
still remains one of the most significant poliovirus 
reservoirs with 998 reported cases of acute flaccid 
paralysis out of which 101 were due to poliovirus 
infection as of early August, 2002. Consequently, 
children can develop poliomyelitis when infected 
by circulating wild polioviruses except they have 
sufficient levels of neutralizing antibodies against 
polioviruses to block the infection.  
 
This study was therefore conducted to determine 
the proportion of infants with protective levels of 
serum neutralizing antibodies after at least two 
doses of OPV among children within the age at 
greatest risk of poliomyelitis in the riverine areas 
(known as hard-to-reach areas because of the 
difficult terrain) as a true biological marker of 
protection against the virus rather than using solely 
the vaccination coverage rate of the National 
Immunization Campaigns in Nigeria. 
MATERIALS AND METHODS 
SAMPLING METHOD 
Random sampling method was used for subject 
selection in this study. Blood samples were 
collected from children aged one week to 10 years 
after due parental consent to participate in the 
study. Healthy vaccinated children were selected at 




immunization days, schools and households. 
Subjects selected were from the riverine 
communities in two local government areas of 
Delta state of Nigeria (5). 
 
SITES AND SAMPLE SIZE 
A total of 200 blood samples were collected from 
children aged one week to 10 years from two local 
government areas in Delta state, Nigeria (Bomadi = 
80, Burutu =120). The samples were collected from 
Bomadi and Kpakiama communities in Bomadi; 
and Burutu, Ogulagha and Odimodi communities 
in Burutu local government area of the state 
(Figure1). 
 
COLLECTION, TRANSPORT, PREPARATION 
AND STORAGE OF SAMPLES 
About 2ml of blood sample was collected by 
venepuncture from each child into a labelled sterile 
container free of anticoagulants or preservatives. 
Samples were transported to the laboratory 
immediately in a cold box with frozen ice packs to 
achieve a condition of about 4 to 8oC. Serum 
samples were separated by low-speed 
centrifugation at 500g for 5 minutes, or direct 
removal of the serum using a sterile disposable 
pipette after retraction of the clot. The serum was 
transferred to two labelled sterile cryovials per 
sample and stored at -20oC until ready for analysis.  
 
The samples were inactivated at 56oC in water bath 
prior to use for neutralization assay.  Virus 
suspensions of the laboratory strain of the three 
poliovirus serotypes (Sabin strains) were prepared 
in L20B cell line. Challenge dose of 100 TCID50 of 
poliovirus serotypes 1, 2 and 3 was determined and 
used for the neutralization test by the standard 
method of constant virus, varying serum dilutions 
microneutralization test as described by WHO (5). 
 












































All serum samples were collected from children 10 
years of age and below. There were 97 males and 
103 females. Overall, 178 (89%), 180 (90%) and 181 
(90.5%) of the 200 blood samples tested had 
antibody titres of 8 or higher against poliovirus 
types 1, 2 and 3, respectively (Table 1). Also, 167 
(83.5%), 160 (80%) and 158 (79%) had antibody titres 
of 32 or higher against poliovirus types 1, 2 and 3, 
respectively (Table 1). Moreover, 162 (81%) had 
antibody titres of 8 or higher against all three 
polioviruses, while 8 (4%) were completely 
seronegative to the three poliovirus serotypes, 2 
(1%) had antibody titre of 8 or higher against P1 
only, 2 (1%) had antibody titre of 8 or higher against 
P2 only and 1 (0.5%) had antibody titre of 8 against 
P3 only. The parents claimed to have received two 
or more doses of OPV for their children. 
 
TABLE 1: NEUTRALIZING ANTIBODIES  





P1        P2 P3 
NO. (%)        NO. (%)          NO. (%)  
≥8 178(89.0) 180(90.0) 181(90.5) 




For the male children, 81 (83.5%), 82 (84.5%) and 83 
(85.6%) had antibody titres of 8 or higher against 
poliovirus types 1, 2 and 3 respectively. However, 
among the female children, 97 (94.2%), 98 (95.1%) 
and 98 (95.1%) had antibody titres of 8 or higher 




Tests for serum neutralizing antibodies are 
considered to be the most specific for evaluation of 
the protective antibody response to poliovirus 
infections. Persons are presumed to be protected 
against disease caused by a particular type of 
poliovirus if they develop type-specific serum 
neutralizing antibodies to the virus. Antibody 
surveys are a more reliable method of assessing 
immunity than either statistics of vaccine uptake (or 
coverage) or sporadic cases or outbreaks of paralytic 
poliomyelitis which signals a dangerous decline of 
immunity due to complacent under vaccination or 
to technical flaws in the vaccination procedure. 
 
This study showed the presence of neutralizing 
antibodies against poliovirus types 1, 2 and 3 in 
children from five riverine communities in two local 
government areas of Delta state, Nigeria. After 
claims to have received at least two doses of oral 
polio vaccine (OPV), by their parents, there was 
variation in the percentage of children 
seroconverting. Overall, 89%, 90% and 90.5% had 
antibody titre of 8 or higher against poliovirus types 
1, 2 and 3, respectively. These results agree with 
reports from other countries where there have also 
been less than optimal responses to trivalent OPV 
(3, 6).  
 
Eighty-one percent (81%) of the children had 
antibody to poliovirus types 1, 2 and 3 at a titre of 8 
or higher. These leave non-immunized pockets of 
children who were seronegative to one or more 
poliovirus types. These non-immunized children, as 
against NPI reports of 108% immunization coverage 
in the second round of the 1999 NIDs, favour 
continued spread and outbreaks of poliovirus 
infection (2, 7). These gaps in immunity levels raise 
concerns of either primary vaccine failure, that is, 
lack of initial antibody responses where potent 
vaccines are used or, failure of the cold chain and 
the subsequent use of non-potent vaccines in the 
field. 
 
Furthermore, the children had 83.5%, 80% and 70% 
seropositivity for poliovirus types 1, 2 and 3, 
respectively, for neutralizing antibody titre of 32 or 
above. Although the level of serum neutralizing 
antibody which protects against clinical illness has 
not been determined, studies have indicated that 
persons with low serum neutralizing antibody titre 
post immunization can be reinfected by wild virus 
or when challenged with vaccine virus (8, 9, 10). In 
animal experiments, passively administered 
antibody that provides moderate serum antibody 
levels (titre of 20 or higher) is likely to protect 
against clinical illness, but this cannot be compared 
with the natural situation where challenge with  
wild or vaccine strains occurs (11). These studies 
suggest that persons with low but detectable serum 
antibody levels are probably not in danger of 
developing clinical poliomyelitis. However, they 
may be reinfected with poliovirus and possibly 
become a source of infection for others who have 
not been vaccinated or have been vaccinated but 
seronegative. 
 
In addition, it was observed that a higher 
percentage of the female children, compared to the 
males, were seropositive to poliovirus types 1, 2 and 
3. On the other hand it was also noticed that 
seropositivity for neutralizing antibodies against 
poliovirus types 1, 2 and 3 is not age dependent. 
Seropositivity did not decrease with increasing age 
of children. This can be explained to be a 
consequence of antibody boosting resulting from 
continuous exposure to the virus in an endemic area 
(9). 
 
The areas where the samples were collected from 
Delta state (Bomadi and Burutu) of Nigeria are 






areas, households are crowded and mostly with 
poor hygiene. Members of a household defecate; 
take their baths, swim and sometime drink from the 
same water source (streams and rivers). Faeces of 
infected children serve as source of contamination 
of water and virus dissemination is facilitated by 
poor sanitation and overcrowding. Ashley et al. (12), 
in a survey in Jamaica obtained sera from more than 
2500 children and adolescents in a population based 
study involving children aged up to 19 years and 
showed that among children 1-4 years that had 
never received vaccine 53%, 77% and 55% were 
seropositive for P1, P2 and P3 respectively, probably 
reflecting circulation of both wild and secondary 
vaccine virus. Circulation of poliovirus due to poor 
sanitation and existence of unhygienic environment 
conditions could be contributing factors to the 
spread of the virus (13). 
 
CONCLUSION 
The present study demonstrates 81% herd 
immunity for the three-poliovirus serotypes among 
children in five riverine communities in two local 
government areas of Delta state of Nigeria. 
Identification of some children without detectable 
antibodies to one or more poliovirus serotypes, in 
their sera, show that pockets of susceptible 
individuals are still present within the population. 
Such individuals favour the continued spread and 
circulation of the virus in the population. Therefore, 
increased vaccination coverage as a result of more 
frequent NIDs, and increased coverage by routine 
immunization in Nigeria, may reduce the number of 
such children and go a long way to ensure the 
eventual elimination of poliomyelitis and wild 
poliovirus from the country.  
 
There is the need to re-evaluate the vaccination 
programmes and implementation of the global polio 
eradication policy in Nigeria to improve 
effectiveness and eventual eradication of polio from 
the country.  Also there is the need for monitoring 
of the various stages of the programme and include 
vaccine potency testing and protective polio 
antibody testing to assess the level of immunity to 
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